Vincerx Pharma, Inc. Common Stock
VINC
VINC was delisted on the 22nd of April, 2025.
56 hedge funds and large institutions have $157M invested in Vincerx Pharma, Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 20 increasing their positions, 8 reducing their positions, and 6 closing their positions.
333% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 6
150% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 8
56% more funds holding
Funds holding: 36 → 56 (+20)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
8% less capital invested
Capital invested by funds: $171M → $157M (-$13.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$8.13M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
+$8.08M |
| 3 |
BC
Boxer Capital
San Diego,
California
|
+$6.85M |
| 4 |
AAA
Affinity Asset Advisors
New York
|
+$4.5M |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$3.85M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
-$9.26M |
| 2 |
PA
Perceptive Advisors
New York
|
-$5.79M |
| 3 |
PI
Putnam Investments
Boston,
Massachusetts
|
-$4.25M |
| 4 |
Verition Fund Management
Greenwich,
Connecticut
|
-$973K |
| 5 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$776K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Legal & General Group
London,
United Kingdom
| $7K | +$8.23K | +27 | New |
|
|
AIP
52
Ameritas Investment Partners
Lincoln,
Nebraska
| $5K | +$5.48K | +18 | New |
|
53
Royal Bank of Canada
Toronto,
Ontario, Canada
| $4K | +$4.88K | +16 | New |
|
54
Citigroup
New York
| $3K | -$67.9K | -223 | -95% |
|
|
AIG
55
American International Group
New York
| $34 | +$40.2K | +132 | New |
|
|
LGM
56
Logos Global Management
San Francisco,
California
| – | -$9.26M | -24,000 | Closed |
|
|
PA
57
Perceptive Advisors
New York
| – | -$5.79M | -15,000 | Closed |
|
|
58
Verition Fund Management
Greenwich,
Connecticut
| – | -$973K | -2,520 | Closed |
|
|
CS
59
Credit Suisse
Zurich,
Switzerland
| – | -$513K | -1,328 | Closed |
|
|
ECM
60
ExodusPoint Capital Management
New York
| – | -$344K | -892 | Closed |
|
61
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$210K | -543 | Closed |
|
|
TRCT
62
Tower Research Capital (TRC)
New York
| – | -$1.83K | -6 | -75% |
|
VINC Hedge Fund Activity: Q2 2021 in Review
56 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Vincerx Pharma, Inc. Common Stock (VINC) for Q2 2021, worth a combined $157M — down 8.1% from $171M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new VINC positions and 6 closed out — a net gain of 20 holders — while 20 added to existing stakes and 8 trimmed.
The largest buyer was Rubric Capital Management (New York), opening a new position worth an estimated $8.13M. The largest seller was Logos Global Management, exiting entirely with an estimated $9.26M sold.
- 56 institutional investors held Vincerx Pharma, Inc. Common Stock (VINC) as of Q2 2021, up from 36 in Q1 2021.
- Funds reported $157M of Vincerx Pharma, Inc. Common Stock stock for Q2 2021, down 8.1% quarter-over-quarter.
- 26 funds opened new Vincerx Pharma, Inc. Common Stock positions in Q2 2021 and 6 closed out, a net change of +20 holders.
- The largest Vincerx Pharma, Inc. Common Stock buyer in Q2 2021 was Rubric Capital Management (New York), an estimated $8.13M added.
- The largest Vincerx Pharma, Inc. Common Stock seller in Q2 2021 was Logos Global Management, an estimated $9.26M sold.
Based on aggregated 13F filings for Q2 2021.